Kenneth I Ataga Selected Research

senicapoc

1/2021	Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
4/2011	Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
2/2009	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
4/2008	Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
11/2006	Dose-escalation study of ICA-17043 in patients with sickle cell disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth I Ataga Research Topics

Disease

53	Sickle Cell Anemia (Hemoglobin S Disease) 12/2021 - 12/2003
15	Hemolysis 12/2021 - 07/2006
10	Pain (Aches) 01/2019 - 02/2009
9	Albuminuria 01/2021 - 09/2010
8	Inflammation (Inflammations) 01/2021 - 07/2006
8	Pulmonary Hypertension 12/2015 - 11/2004
5	Thalassemia 01/2019 - 01/2012
5	Acute Pain 01/2018 - 03/2010
5	Acute Chest Syndrome 12/2014 - 10/2011
4	Anemia 12/2021 - 11/2018
4	Stroke (Strokes) 01/2019 - 09/2010
3	Hemolytic Anemia 05/2021 - 10/2007
3	Kidney Diseases (Kidney Disease) 01/2021 - 01/2018
3	Reperfusion Injury 01/2016 - 11/2008
2	Fever (Fevers) 11/2019 - 06/2012
2	Necrosis 01/2019 - 11/2007
2	Proteinuria 01/2019 - 05/2014
2	Thrombosis (Thrombus) 01/2019 - 09/2013
2	Hypertension (High Blood Pressure) 09/2014 - 06/2014
2	Chronic Kidney Failure (Chronic Renal Failure) 09/2014 - 06/2014
2	beta-Thalassemia (Cooley's Anemia) 11/2008 - 12/2003
2	Thrombophilia 11/2008 - 12/2003
1	Renal Insufficiency (Renal Failure) 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Chronic Disease (Chronic Diseases) 05/2021
1	Disease Progression 01/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020
1	Malaria 11/2018
1	Infections 11/2018
1	Glucosephosphate Dehydrogenase Deficiency 11/2018
1	Body Weight (Weight, Body) 01/2017
1	Seizures (Absence Seizure) 05/2014
1	Hemorrhage 09/2013
1	Rare Diseases (Rare Disease) 04/2013
1	Low Back Pain (Lumbago) 06/2012

Drug/Important Bio-Agent (IBA)

9	Hemoglobins (Hemoglobin)IBA 01/2020 - 12/2003
8	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2021 - 06/2014
5	Biomarkers (Surrogate Marker)IBA 12/2021 - 10/2011
5	senicapocIBA 01/2021 - 11/2006
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2019 - 06/2014
4	Angiotensin Receptor AntagonistsIBA 01/2019 - 06/2014
4	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2016 - 02/2011
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2016 - 05/2007
3	CreatinineIBA 01/2022 - 09/2010
3	Pharmaceutical PreparationsIBA 05/2021 - 09/2015
3	P-SelectinIBA 01/2019 - 05/2012
3	crizanlizumabIBA 01/2019 - 01/2017
3	Eptifibatide (Integrilin)FDA Link 01/2018 - 11/2007
3	AlbuminsIBA 01/2018 - 09/2010
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 05/2021 - 01/2012
2	BilirubinIBA 05/2021 - 01/2012
2	voxelotorIBA 05/2021 - 01/2019
2	Atorvastatin (Lipitor)FDA Link 11/2019 - 01/2018
2	Sickle HemoglobinIBA 01/2019 - 11/2013
2	GlobinsIBA 11/2018 - 11/2013
2	Fetal Hemoglobin (Hemoglobin F)IBA 10/2017 - 11/2004
2	Endothelin-1 (Endothelin 1)IBA 01/2016 - 03/2010
2	Hemostatics (Antihemorrhagics)IBA 09/2013 - 11/2008
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 02/2013 - 11/2008
2	CD40 Ligand (CD40L)IBA 01/2012 - 07/2006
2	PotassiumIBA 04/2011 - 02/2009
2	Tyrosine (L-Tyrosine)FDA Link 02/2011 - 09/2010
2	AnticoagulantsIBA 11/2008 - 01/2007
2	Thromboplastin (Tissue Factor)IBA 01/2007 - 07/2006
2	Thrombin FDA Link 01/2007 - 12/2003
1	RivaroxabanIBA 01/2021
1	Factor Xa InhibitorsIBA 01/2021
1	Cell Adhesion MoleculesIBA 01/2019
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2019
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 11/2018
1	Ferritins (Ferritin)IBA 11/2018
1	MicronutrientsIBA 11/2018
1	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 11/2018
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018
1	nephrinIBA 01/2018
1	NKTT120IBA 01/2017
1	Monoclonal AntibodiesIBA 01/2017
1	Biological ProductsIBA 01/2016
1	PhosphatidylserinesIBA 01/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2016
1	hemoglobin AAIBA 11/2015
1	CholesterolIBA 06/2015
1	HDL CholesterolIBA 06/2015
1	Oxygen (Dioxygen)IBA 12/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2014
1	Narcotics (Narcotic Analgesics)IBA 05/2014
1	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2014
1	2,2-dimethylbutyric acidIBA 11/2013
1	Analgesics (Analgesic Drugs)IBA 04/2013
1	Opioid Analgesics (Opioids)IBA 04/2013
1	Prasugrel Hydrochloride FDA Link 02/2013

Therapy/Procedure

13	Therapeutics 12/2021 - 07/2006
2	Kidney Transplantation 01/2022 - 09/2014
2	Drug Therapy (Chemotherapy) 01/2020 - 01/2018
1	Transitional Care 10/2021
1	Endarterectomy (Thromboendarterectomy) 12/2015
1	Artificial Respiration (Mechanical Ventilation) 12/2014
1	Patient-Controlled Analgesia (Analgesia, Patient Controlled) 04/2013
1	Pain Management 04/2013